{"entity": "researcher", "timestamp": "2026-08-20T20:36:17.665Z", "family": "Nestor", "given": "Marika", "initials": "M", "orcid": "0000-0003-4662-3142", "affiliations": ["Department of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala University, Uppsala, Sweden."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/11ccea08af3f404bbdf67a68ee8f1de4.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/11ccea08af3f404bbdf67a68ee8f1de4"}}, "publications": [{"entity": "publication", "iuid": "e1a9e93abdc94a7aac7484a984c1d973", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/e1a9e93abdc94a7aac7484a984c1d973.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/e1a9e93abdc94a7aac7484a984c1d973"}}, "title": "Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts.", "authors": [{"family": "Lundgren Mortensen", "given": "Anja Charlotte", "initials": "AC", "orcid": "0000-0002-6771-3289", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/85c16524674b49e5a8d24fdae955e8f2.json"}}, {"family": "Berglund", "given": "Hanna", "initials": "H", "orcid": "0009-0007-1754-1822", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/e89dca9798db436499e12cf23291e1d3.json"}}, {"family": "Jha", "given": "Preeti", "initials": "P", "orcid": "0000-0001-9943-5976", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/4229e04c150b47458431de671cc0e05b.json"}}, {"family": "Stenman", "given": "Adam", "initials": "A", "orcid": "0000-0003-3248-7629", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8fd6c3e9b7644d7c90708d1250ea008b.json"}}, {"family": "Selvaraju", "given": "Ram Kumar", "initials": "RK", "orcid": "0000-0001-9219-1497", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/83711532c31f4f1dad8bd6c3495b9c08.json"}}, {"family": "Lundqvist", "given": "Hans", "initials": "H", "orcid": "0009-0002-4859-1332", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/7f729923c1c74e3a8015e1b76500e97f.json"}}, {"family": "Hofstr\u00f6m", "given": "Camilla", "initials": "C", "orcid": "0009-0008-6407-9893", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/30fb64ebeda84e4bbf280166f56ec46f.json"}}, {"family": "Persson", "given": "Helena", "initials": "H", "orcid": "0009-0004-6053-0801", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/aba54ede629f4464b916d9d734859cc0.json"}}, {"family": "Juhlin", "given": "C Christofer", "initials": "CC", "orcid": "0000-0002-5945-9081", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/c155b3a3146b41909170a016a7f5b07a.json"}}, {"family": "Zedenius", "given": "Jan", "initials": "J", "orcid": "0000-0003-2833-3758", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/d3ff2a15cd7d4d8aa46b15c0e2d0f261.json"}}, {"family": "Frejd", "given": "Fredrik Y", "initials": "FY", "orcid": "0000-0002-6421-4142", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/0bf87385618f44ddae90e48177849e4e.json"}}, {"family": "Nestor", "given": "Marika", "initials": "M", "orcid": "0000-0003-4662-3142", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/11ccea08af3f404bbdf67a68ee8f1de4.json"}}], "type": "journal article", "published": "2025-05-02", "journal": {"title": "Mol. Cancer Ther.", "issn": "1538-8514", "volume": "24", "issue": "5", "pages": "753-762", "issn-l": "1535-7163"}, "abstract": "Anaplastic thyroid cancer (ATC) is a rare but severe form of thyroid cancer responsible for approximately 50% of thyroid cancer deaths. Consequently, the identification of innovative therapies remains crucial for the effective treatment of ATC. Molecular radiotherapy is a rapidly growing field within oncology, and the cell surface antigen CD44v6, which is overexpressed in several cancers, is a plausible target for molecular radiotherapy of ATC. IHC of 39 patient samples with ATC was evaluated for CD44v6 expression. Biodistribution and dosimetry of iodine-125 (125I)-/lutetium-177 (177Lu)-labeled UU-40, a CD44v6-specific antibody, followed by in vivo efficacy in two ATC xenograft models with varying target expression levels (ACT-1 and BHT-101), accompanied by single-photon emission computed tomography (SPECT) imaging, evaluated radiolabeled UU-40 for therapeutic efficiency in ATC xenografts. The IHC revealed CD44v6 immunoreactivity in 46% of patient samples with ATC. The biodistribution favored 177Lu-labeled UU-40 over the 125I-labeled antibody and confirmed the in vivo specificity of both radioconjugates. The in vivo efficacy and accompanied SPECT imaging of a moderate CD44v6-expressing xenograft model (BHT-101) verified the tumor specificity, as well as the target-specific effect of 177Lu-labeled UU-40 on tumor growth and survival. A 100% complete response rate was demonstrated as a result of therapy using a single dose of 16 MBq 177Lu-labeled UU-40 in a high CD44v6-expressing xenograft model (ACT-1), and SPECT imaging revealed excellent tumor uptake of the radioconjugate at 14 days after injection. This study verifies the expression of CD44v6 in ATC and strengthens the superiority and promise of 177Lu-labeled UU-40 over 131I-labeled UU-40 for antibody-based molecular radiotherapy of CD44v6-positive ATC.", "doi": "10.1158/1535-7163.MCT-24-0524", "pmid": "39976160", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC12046332"}, {"db": "pii", "key": "752016"}], "notes": [], "created": "2026-08-20T12:12:49.341Z", "modified": "2026-08-20T12:12:49.856Z"}, {"entity": "publication", "iuid": "b5bb98359cd84a668c9930a8aaef2d6b", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/b5bb98359cd84a668c9930a8aaef2d6b.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/b5bb98359cd84a668c9930a8aaef2d6b"}}, "title": "Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 with PEG-Stabilized Lipodisks.", "authors": [{"family": "Lundsten", "given": "Sara", "initials": "S", "orcid": "0000-0002-0063-3233", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/563c0965e9e1492ebda5919f46744299.json"}}, {"family": "Hern\u00e1ndez", "given": "V\u00edctor Agmo", "initials": "VA", "orcid": "0000-0002-6733-3227", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/fe456d28a86743b694e8f9ba927421ad.json"}}, {"family": "Gedda", "given": "Lars", "initials": "L"}, {"family": "Sar\u00e9n", "given": "Tina", "initials": "T"}, {"family": "Brown", "given": "Christopher J", "initials": "CJ"}, {"family": "Lane", "given": "David P", "initials": "DP"}, {"family": "Edwards", "given": "Katarina", "initials": "K"}, {"family": "Nestor", "given": "Marika", "initials": "M", "orcid": "0000-0003-4662-3142", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/11ccea08af3f404bbdf67a68ee8f1de4.json"}}], "type": "journal article", "published": "2020-04-19", "journal": {"title": "Nanomaterials (Basel)", "issn": "2079-4991", "volume": "10", "issue": "4", "issn-l": null}, "abstract": "Stapled peptides targeting the interaction between p53 and its negative regulators MDM2 and MDM4 have exhibited great potential as anti-cancer drugs, albeit with room for improvement in formulation and tumor specificity. Lipid bilayer disks (lipodisks) have emerged as promising drug nanocarriers and can by attachment of targeting moieties be directed selectively towards tumor cells. Tumor-targeted delivery of stapled peptides by use of lipodisks may therefore increase the uptake in the tumors and limit toxicity in healthy tissue. Here, we utilized epidermal growth factor receptor (EGFR)-targeted lipodisks to deliver p53-activating stapled peptide VIP116 to EGFR-expressing tumor cells. We demonstrate that VIP116 can be stably formulated in lipodisks (maximum peptide/lipid molar ratio 0.11). In vitro cell studies verify specific binding of EGF-decorated lipodisks to tumor cells and confirm that targeted delivery of VIP116 significantly decreases tumor cell viability.", "doi": "10.3390/nano10040783", "pmid": "32325827", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC7221704"}, {"db": "pii", "key": "nano10040783"}], "notes": [], "created": "2026-08-20T13:42:42.435Z", "modified": "2026-08-20T13:42:42.554Z"}]}